Iovance Biotherapeutics Inc. diskutieren
Iovance Biotherapeutics Inc.
WKN: A2DT49 / Symbol: IOVA / Name: Iovance Biotherapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
1,90 €
5,75 %
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $21.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Robert W. Baird from $24.00 to $20.00. They now have an "outperform" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Chardan Capital from $34.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $22.00 to $19.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Barclays PLC from $22.00 to $5.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $16.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at HC Wainwright from $32.00 to $20.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Chardan Capital from $30.00 to $25.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Barclays PLC from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Mizuho from $30.00 to $10.00. They now have an "outperform" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $16.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Neueste Beiträge
BTIG_Research in Workday, Inc. diskutieren